Medical Device | February 23, 2022
MicroLumix’ GermPass kills Covid-19 virus in five seconds
New biotechnology product aims to be world's fastest automatic sanitary solution
New biotechnology product aims to be world's fastest automatic sanitary solution
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Appoints Dr Rafiq Hasan as CEO
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
Subscribe To Our Newsletter & Stay Updated
